<!DOCTYPE html>
<html lang="en">
	<head>
		<meta charset="UTF-8">
		<title>Agnes Basseville | Academic personal website</title>
		<link href='http://fonts.googleapis.com/css?family=Nixie+One|Open+Sans:300|Pacifico' rel='stylesheet' type='text/css'>
		<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
		<link rel="stylesheet" href="css/ForGithub.css">
	</head>
	<body>
		<!-- Header & Nav -->
		<header>
			<div>
				<h1>Agnes Basseville, PhD</h1>
				<h2>Omics and Data Science Unit / ICO </h2>
			</div>
			<nav>
				<a href="/">Home</a>
				<a href="/Projects.html">Projects</a>
				<a href="/Publications.html"class="active-class">Publications</a>
				<a href="/Resume.html">Resume</a>
				<a href="/Team.html">Team</a>
			</nav>
		</header>

		<!-- main content -->
		<main role="main">
			<!-- <img class="profile-img" src="images/profile.jpg" alt="description of image"> -->
			
			<h1>Publications</h1>
			<br>
			
			<h3>2024</h3>
			
			<UL>
			<LI> Safari M, Scotto L, <b>Basseville A</b>, Litman T, Xue H, Petrukhin L, Zhou P, Morales DV, Damoci C, Zhu M, Hull K, Olive KP, Fojo T, Romo D, Bates SE. Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma. 
			BioRxiv, 2024 July. 
			<a href="https://www.biorxiv.org/content/10.1101/2024.06.30.600495v1"target="_blank">DOI: 10.1101/2024.06.30.600495</a>     
			<LI> Jézéquel P, Lasla H, Gouraud W, <b>Basseville A</b>, Michel B, Frenel JS, Juin PP, Ben Azzouz F, Campone M. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype. 
			Breast Cancer, 2024 May. 
			<a href="https://doi.org/10.1007/s12282-024-01597-z"target="_blank">DOI: 10.1007/s12282-024-01597-z</a>. Link for the accepted manuscript version: <a href="images/2024_TNBC_subtype_BreastCancer.pdf"target="_blank">PDF</a>     
			</UL>
			<br>
			
			<h3>2022</h3>
			
			<UL>
			<LI> Bonneaud TL, Lefebvre CC, Nocquet L, <b>Basseville A</b>, Roul J, Weber H, Campone M, Juin PP, Souazé F. Targeting of MCL-1 in breast cancer associated fibroblasts 
			reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death & Disease, 2022 Sept. 
			<a href="https://doi.org/10.1038/s41419-022-05214-9"target="_blank">DOI: 10.1038/s41419-022-05214-9</a>    <!-- target="_blank": new tab-->
			<LI> <b>Basseville A</b>, Cordier C, Ben Azzouz F, Gouraud W, Lasla H, Panloup F, Campone M, Jézéquel P. Brain neural progenitors are new predictive biomarkers for breast 
			cancer hormonotherapy. Cancer Research Communications. 2022 Jul. <a href="https://doi.org/10.1158/2767-9764.CRC-21-0090"target="_blank">DOI: 10.1158/2767-9764.CRC-21-0090</a>
			<LI>  <b>Basseville A</b>, Violet PC, Safari M, Sourbier C, Linehan WM, Robey RW, Levine M, Sackett DL, Bates SE. A Histone deacetylase inhibitor induces acetyl-CoA depletion leading to 
			lethal metabolic stress in RAS-pathway activated cells. Cancers. 2022 May, 14(11), 2643.
			<a href="https://doi.org/10.3390/cancers14112643"target="_blank">DOI: 10.3390/cancers14112643</a>   
			<LI>  Robey RW, Lusvarghi S, Chau CH, <b>Basseville A</b>,  Figg WD, Ambudkar SV, Bates SE. Drug transporters: molecular characterization and role in drug disposition, 3rd edition, Chapter 12. 
			Guofeng You & Marilyn Morris (Eds). New York, John Wiley and Sons, 2022 April.
			<a href="https://doi.org/10.1002/9781119739883.ch12"target="_blank">DOI: 10.1002/9781119739883.ch12</a>   
			<LI>  Belaid NM,  <b>Basseville A</b>,  Andre-Grégoire G, Fetiveau A, Maillet L, Guillonneau F, Leduc M, Guette C, Desaubry L, Gavard J, Gautier F, Juin PP. BCL-xL antagonizes the deleterious effects of 
			KRAS on mitochondrial scaffolding. Biorxiv preprint, 2022 April.
			<a href="https://doi.org/10.1101/2022.04.13.488211"target="_blank">DOI: 10.1101/2022.04.13.488211</a>    
			</UL>
			<br>
			
			<h3>2021</h3>
			<UL>
			<LI> Jézéquel P, Gouraud W, Ben Azzouz F, <b>Basseville A</b>, Juin PP, Lasla H, Campone M. Intérêt de l’outil web bc-GenExMiner en oncologie.Bull Cancer 2021 Nov.
			<a href="https://doi.org/10.1016/j.bulcan.2021.05.008"target="_blank">DOI: 10.1016/j.bulcan.2021.05.008 </a>  
			<LI> Safari M, Litman T, Robey RW, Aguilera A, Chakraborty A, Reinhold W, <b>Basseville A</b>, Petrukhin L, Scotto L, O'Connor O, Pommier Y, Fojo A, Bates SE. R-loop-Mediated ssDNA Breaks Accumulate Following 
			Short-Term Exposure to the HDAC Inhibitor Romidepsin. Mol Cancer Research, 2021 June.
			<a href="https://doi.org/10.1158/1541-7786.MCR-20-0833"target="_blank">DOI: 10.1158/1541-7786.MCR-20-0833</a>
            </UL>			
			<br>
			
			<h3>2017</h3>
			<UL>
			<LI> Carné Trécesson S, Souazé F, <b>Basseville A</b>, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP. BCL-X(L) directly 
			modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017 Oct.
			<a href="https://doi.org/10.1038/s41467-017-01079-1"target="_blank">DOI: 10.1038/s41467-017-01079-1</a>   
			</UL>
			<br>
			
			<h3>2016</h3>
			<UL>
			<LI> Bahr JC, Robey RW, Luchenko V, <b>Basseville A</b>, Chakraborty AR, Kozlowski H,Pauly GT, Patel P, Schneider JP, Gottesman MM, Bates SE. Blocking downstream signaling pathways in the context of HDAC inhibition promotes 
			apoptosis preferentially in cells harboring mutant Ras. Oncotarget. 2016 Oct.
			<a href="https://doi.org/10.18632/oncotarget.12001"target="_blank">DOI: 10.18632/oncotarget.12001</a>   
			<LI> <b>Basseville A</b>, Hall MD, Chau CH, Robey RW, Gottesman MM, Figg WD, Bates SE. ABC Transporters, 40 Years on, Chapter 9. Anthony M. George (Ed.). Springer International Publishing, 2016 Dec. 
			<a href="https://doi.org/10.1007/978-3-319-23476-2_9"target="_blank">DOI: 10.1007/978-3-319-23476-2_9</a>   
			</UL>
			<br>
			
			<h3>2015</h3>
			<UL>
			<LI> <b>Basseville A</b>, Bates S, Fojo T. Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules. Nat Rev Clin Oncol, 2015 Aug. 
			<a href="https://doi.org/10.1038/nrclinonc.2015.125"target="_blank">DOI: 10.1038/nrclinonc.2015.125</a>    
			<LI> Serrano OK, Parrow NL, Violet PC, Yang J, Zornjak J, <b>Basseville A</b>, Levine M. Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model. Free Radic Biol Med, 2015 Oct. 
			<a href="https://doi.org/10.1016/j.freeradbiomed.2015.06.032"target="_blank">DOI: 10.1016/j.freeradbiomed.2015.06.032</a>   
			</UL>
			<br>
			
			<h3>2014</h3>
			<UL>
			<LI> <b>Basseville A</b>, Robey RW, Bahr JC, Bates SE. Drug transporters: molecular characterization and role in drug disposition, Chapter 11. Guofeng You & Marilyn Morris (Eds). New York, John Wiley and Sons, 2014 Aug. 
			<a href="https://doi.org/10.1002/9781118705308.ch11"target="_blank">DOI: 10.1002/9781118705308.ch11</a>  
		    </UL>
			<br>
			
			<h3>2013</h3>
			<UL>
			<LI> Ierano C, <b>Basseville A</b>, To KK, Zhan Z, Robey RW, Wilkerson J, Bates SE, Scala S. Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. Cancer Biol Ther, 
			2013 Feb.
			<a href="https://doi.org/10.4161/cbt.22957"target="_blank">DOI: 10.4161/cbt.22957</a>   
			<LI> <b>Basseville A</b>, Figg WD, Sparreboom A, Bates SE. Pharmacogenomics of Human Drug Transporters: Clinical Impacts, Chapter 14.Toshihisa Ishikawa, Richard B. Kim & Jörg König (Eds). 
			New York, John Wiley and Sons, 2013 Mar.
			<a href="https://doi.org/10.1002/9781118353240.ch14"target="_blank">DOI: 10.1002/9781118353240.ch14 </a>    
			</UL>
			<br>
			
			<h3>2012</h3>
			<UL>
			<LI> <b>Basseville A</b>, Tamaki A, Ierano C, Trostel S, Ward Y, Robey R, Hegde RS, Bates SE. Cancer Res, 2012 Jul. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking 
			of a common polymorphic variant of the ABCG2 efflux transporter. 2015 Jul.
			<a href="https://doi.org/10.1158/0008-5472.CAN-11-2008"target="_blank">DOI: 10.1158/0008-5472.CAN-11-2008  </a>   
			<LI> Amiri-Kordestani L, <b>Basseville A</b>, Kurdziel K, Fojo AT, Bates SE. Drug Resist Updat, Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal
			studies. 2012 Mar.
			<a href="https://doi.org/10.1016/j.drup.2012.02.002"target="_blank">DOI: 10.1016/j.drup.2012.02.002 </a>   
			</UL>
			<br>
			
			<h3>2011</h3>
			<UL>
			<LI> Robey RW, Chakraborty AR, <b>Basseville A</b>, Luchenko V, Bahr J, Zhan Z, Bates SE. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm, 2011 Dec.
			<a href="https://doi.org/10.1021/mp200329f"target="_blank">DOI: 10.1021/mp200329f  </a>   
			<LI> <b>Basseville A</b> & Bates SE. Gout, genetics and ABC transporters. F1000 Biol Rep, 2011. Nov.
			<a href="https://doi.org/10.3410/B3-23"target="_blank">DOI: 10.3410/B3-23  </a>   
			<LI> <b>Basseville A</b>, Preisser L, de Carné Trécesson S, Boisdron-Celle M, Gamelin E, Coqueret O, Morel A. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer 
				cells. Mol Cancer, 2011 Jul.
			<a href="https://doi.org/10.1186/1476-4598-10-80 "target="_blank">DOI: 10.1186/1476-4598-10-80     </a>   
		    </UL>
			<br>
			<br>
			
			
		</main>

		<!-- page footer -->
		<footer>
		<br>
			<p>&#169; 2024. All rights reserved</p>
		</footer>
	</body>
</html>
